Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intuniv for Aggression and Self-injury in Prader-Willi Syndrome
NCT05657860Phase 4Completed
- Sponsor
- Maimonides Medical Center
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of guanfacine in Self-injurious behavior, sponsored by Maimonides Medical Center. Started Dec 2020; status: completed.
02
Drugs
guanfacine
03
Conditions
Self-injurious behavior
Beyond the preview
Go deeper on NCT05657860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657860.